GSK fights bid to strike new Zofran preemption evidence

U.S. District Judge F. Dennis Saylor during a hearing in Boston asked why some of GSK's witnesses should be allowed to put forward new opinions to support the drugmaker's defence after an August 2018 deadline for expert reports had lapsed.

New Delhi: A federal judge on Wednesday signalled he may strike some new evidence GlaxoSmithKline Plc put forward in its renewed bid to argue federal law preempts state law claims in a case that alleges the company failed to warn that its anti-nausea drug Zofran can cause birth defects.

Read Also: GSK gets USFDA nod for Nucala, only biologic to treat eosinophilic asthma in the age group 6-11 year

U.S. District Judge F. Dennis Saylor during a hearing in Boston asked why some of GSK's witnesses should be allowed to put forward new opinions to support the drugmaker's defence after an August 2018 deadline for expert reports had lapsed.

Read Also: GSK Pharma sells 60 acres land in Thane to Oberoi Realty for Rs 890 crore